JP2024516430A5 - - Google Patents
Info
- Publication number
- JP2024516430A5 JP2024516430A5 JP2023566849A JP2023566849A JP2024516430A5 JP 2024516430 A5 JP2024516430 A5 JP 2024516430A5 JP 2023566849 A JP2023566849 A JP 2023566849A JP 2023566849 A JP2023566849 A JP 2023566849A JP 2024516430 A5 JP2024516430 A5 JP 2024516430A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- methyl
- pyrimidine
- methoxy
- dimethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/091463 | 2021-04-30 | ||
| CN2021091463 | 2021-04-30 | ||
| PCT/CN2022/090836 WO2022228578A1 (en) | 2021-04-30 | 2022-05-02 | Pyrimidinylaminobenzenes for lung cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516430A JP2024516430A (ja) | 2024-04-15 |
| JP2024516430A5 true JP2024516430A5 (https=) | 2025-06-05 |
Family
ID=83847794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566849A Pending JP2024516430A (ja) | 2021-04-30 | 2022-05-02 | 肺がん治療のためのピリミジニルアミノベンゼン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240226101A1 (https=) |
| EP (1) | EP4330256A4 (https=) |
| JP (1) | JP2024516430A (https=) |
| KR (1) | KR20240027583A (https=) |
| CN (1) | CN117561254A (https=) |
| WO (1) | WO2022228578A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024094064A1 (en) * | 2022-11-02 | 2024-05-10 | Suzhou Puhe Biopharma Co., Ltd | Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis |
| CN116098873A (zh) * | 2023-03-08 | 2023-05-12 | 苏州浦合医药科技有限公司 | 一种药物制剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761544B (zh) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| CN105085489B (zh) * | 2014-11-05 | 2019-03-01 | 益方生物科技（上海）有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| CN106279160B (zh) * | 2016-03-18 | 2017-09-26 | 海南越康生物医药有限公司 | N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途 |
| MX383920B (es) * | 2016-05-26 | 2025-03-14 | Recurium Ip Holdings Llc | Compuestos inhibidores de egfr. |
| EP3585389A4 (en) * | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS |
| JP7028900B2 (ja) * | 2017-06-13 | 2022-03-02 | ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー | アミノピリミジン化合物、その調製方法、およびその使用 |
| EP3641818A1 (en) * | 2017-06-23 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for preventing or treating cancer resistance to egfr inhibition |
| CN111093645A (zh) * | 2017-07-05 | 2020-05-01 | Cs制药技术有限公司 | Egfr酪氨酸激酶的临床上重要的突变体的选择性抑制剂 |
| CN107266437B (zh) * | 2017-07-19 | 2019-08-30 | 海南越康生物医药有限公司 | N-苯基-2-氨基嘧啶类化合物的晶型、盐型及其制备方法 |
| JP2021513517A (ja) * | 2018-02-12 | 2021-05-27 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 非小細胞肺がんの治療に使用するためのオシメルチニブ |
| CN111588710B (zh) * | 2019-02-21 | 2023-06-20 | 浙江大学 | 一种针对egfr耐药突变c797s的联用药物及用途 |
| CN111747950B (zh) * | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
-
2022
- 2022-05-02 US US18/558,522 patent/US20240226101A1/en active Pending
- 2022-05-02 EP EP22795047.4A patent/EP4330256A4/en not_active Withdrawn
- 2022-05-02 KR KR1020237040518A patent/KR20240027583A/ko active Pending
- 2022-05-02 CN CN202280031627.6A patent/CN117561254A/zh active Pending
- 2022-05-02 WO PCT/CN2022/090836 patent/WO2022228578A1/en not_active Ceased
- 2022-05-02 JP JP2023566849A patent/JP2024516430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3515916B1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| JP2022546520A (ja) | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 | |
| CN108366992A (zh) | 蛋白水解靶向嵌合体化合物及其制备和应用方法 | |
| ME02340B (me) | Triciklična jedinjenja | |
| WO2008076415A1 (en) | Methods of using mek inhibitors | |
| JP2003500404A5 (https=) | ||
| US12415808B2 (en) | Pyrrolo[1,2-b]pyridazine derivatives | |
| JP2024516430A5 (https=) | ||
| JP2014528464A5 (https=) | ||
| JP2006528231A (ja) | プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物 | |
| JPWO2021060453A5 (https=) | ||
| TWI840311B (zh) | Rip1k抑制劑 | |
| JP2018509442A (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| JP2024517765A (ja) | インテグリン阻害剤の拡大投与レジメン | |
| AU2019320770A1 (en) | Thiadiazole IRAK4 inhibitors | |
| HRP20110332T1 (hr) | TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3 | |
| JP2023002695A (ja) | ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体 | |
| EP3837012A1 (en) | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors | |
| EP4735426A1 (en) | Heteroaromatic dhodh inhibitors | |
| WO2023118092A1 (en) | Pyrazolo[1,5-a]pyrido[3,2-e]pyrimidines and pyrazolo[1,5-a][1,3]thiazolo[5,4-e]pyrimidines as p2x3 inhibitors for the treatment of neurogenic disorders | |
| JP2002114786A5 (https=) | ||
| WO2025168756A1 (en) | Pyrrolopyrazine compounds and their use in therapy | |
| EA048929B1 (ru) | Соединения, ингибирующие rip1, и способы их получения и применения | |
| HK1134784B (en) | Methods of using mek inhibitors | |
| HK1134784A (en) | Methods of using mek inhibitors |